These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 20526762)

  • 1. Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes.
    Taskinen MR; Barter PJ; Ehnholm C; Sullivan DR; Mann K; Simes J; Best JD; Hamwood S; Keech AC;
    Diabetologia; 2010 Sep; 53(9):1846-55. PubMed ID: 20526762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
    d'Emden MC; Jenkins AJ; Li L; Zannino D; Mann KP; Best JD; Stuckey BG; Park K; Saltevo J; Keech AC;
    Diabetologia; 2014 Nov; 57(11):2296-303. PubMed ID: 25149070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk.
    Walldius G; Jungner I; Aastveit AH; Holme I; Furberg CD; Sniderman AD
    Clin Chem Lab Med; 2004; 42(12):1355-63. PubMed ID: 15576296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex-specific differences in blood lipids and lipid ratios in type 2 diabetic foot patients.
    Yin S; Zhao P; Ai Z; Deng B; Jia W; Wang H; Zheng J
    J Diabetes Investig; 2021 Dec; 12(12):2203-2211. PubMed ID: 34137504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).
    Albers JJ; Slee A; O'Brien KD; Robinson JG; Kashyap ML; Kwiterovich PO; Xu P; Marcovina SM
    J Am Coll Cardiol; 2013 Oct; 62(17):1575-9. PubMed ID: 23973688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study.
    Bruno G; Merletti F; Biggeri A; Bargero G; Prina-Cerai S; Pagano G; Cavallo-Perin P
    Diabetologia; 2006 May; 49(5):937-44. PubMed ID: 16525840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease.
    Welsh C; Celis-Morales CA; Brown R; Mackay DF; Lewsey J; Mark PB; Gray SR; Ferguson LD; Anderson JJ; Lyall DM; Cleland JG; Jhund PS; Gill JMR; Pell JP; Sattar N; Welsh P
    Circulation; 2019 Aug; 140(7):542-552. PubMed ID: 31216866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls.
    Parish S; Peto R; Palmer A; Clarke R; Lewington S; Offer A; Whitlock G; Clark S; Youngman L; Sleight P; Collins R;
    Eur Heart J; 2009 Sep; 30(17):2137-46. PubMed ID: 19520708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio.
    Kappelle PJ; Gansevoort RT; Hillege HJ; Wolffenbuttel BH; Dullaart RP;
    J Clin Lipidol; 2013; 7(1):56-64. PubMed ID: 23351584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of corpulence parameters and haemoglobin A1c on metabolic control in type 2 diabetic patients: comparison of apolipoprotein B/A-I ratio with fasting and postprandial conventional lipid ratios.
    Diaf M; Khaled BM; Sellam F
    Libyan J Med; 2015; 10(1):27400. PubMed ID: 25959906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of gender, age and menopausal status on serum apolipoprotein concentrations.
    Anagnostis P; Stevenson JC; Crook D; Johnston DG; Godsland IF
    Clin Endocrinol (Oxf); 2016 Nov; 85(5):733-740. PubMed ID: 27086565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort.
    Mariosa D; Hammar N; Malmström H; Ingre C; Jungner I; Ye W; Fang F; Walldius G
    Ann Neurol; 2017 May; 81(5):718-728. PubMed ID: 28437840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes.
    Jiang R; Schulze MB; Li T; Rifai N; Stampfer MJ; Rimm EB; Hu FB
    Diabetes Care; 2004 Aug; 27(8):1991-7. PubMed ID: 15277429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.
    Hiukka A; Leinonen E; Jauhiainen M; Sundvall J; Ehnholm C; Keech AC; Taskinen MR
    Diabetologia; 2007 Oct; 50(10):2067-75. PubMed ID: 17653691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma concentrations of lipoproteins and risk of lower-limb peripheral artery disease in people with type 2 diabetes: the SURDIAGENE study.
    Bertrand C; Saulnier PJ; Potier L; Croyal M; Blanchard V; Gand E; Ragot S; Schneider F; Bocock O; Baillet-Blanco L; Velho G; Marre M; Roussel R; Rigalleau V; Hadjadj S; Mohammedi K;
    Diabetologia; 2021 Mar; 64(3):668-680. PubMed ID: 33409569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations of apolipoprotein B/apolipoprotein A-I ratio with pre-diabetes and diabetes risks: a cross-sectional study in Chinese adults.
    Zheng S; Han T; Xu H; Zhou H; Ren X; Wu P; Zheng J; Wang L; Zhang M; Jiang Y; Chen Y; Qiu H; Liu W; Hu Y
    BMJ Open; 2017 Jan; 7(1):e014038. PubMed ID: 28110289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LDL-C/apoB and HDL-C/apoA-1 ratios predict incident chronic kidney disease in a large apparently healthy cohort.
    Bae JC; Han JM; Kwon S; Jee JH; Yu TY; Lee MK; Kim JH
    Atherosclerosis; 2016 Aug; 251():170-176. PubMed ID: 27341533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).
    Charlton-Menys V; Betteridge DJ; Colhoun H; Fuller J; France M; Hitman GA; Livingstone SJ; Neil HA; Newman CB; Szarek M; DeMicco DA; Durrington PN
    Diabetologia; 2009 Feb; 52(2):218-25. PubMed ID: 18972097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.